Premium
Pharmacokinetics of 51W89: preliminary data
Author(s) -
HUNTER J. M.,
EASTWOOD N. B.,
BOYD A. H.,
PARKER C. J. R.
Publication year - 1995
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1995.tb04318.x
Subject(s) - medicine , pharmacokinetics , metabolite , bolus (digestion) , renal function , dialysis , intravenous bolus , plasma concentration , half life , chronic renal failure , urology , anesthesia , pharmacology
The pharmacokinetics of the 1R cis ‐1'R cis ‐isomer of atracurium (51W89) and its metabolite, laudanosine, were studied in 11 healthy patients with normal renal function and in 12 patients with chronic renal failure undergoing regular dialysis. A bolus dose of 51W89 (0.1 mg/kg) was given, and the plasma concentration was measured at regular intervals for 480 min. The elimination half‐life of 51W89 was significantly longer in renal failure patients than in healthy controls (38.9 min vs 30.6 min; P (0.05). The plasma laudanosine levels were lower than those reported after an equipotent dose of atracurium besylate. 51W89 may have a prolonged effect in renal failure patients.